PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
55 hedge funds and large institutions have $113M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 19 closing their positions.
164% more call options, than puts
Call options by funds: $119K | Put options by funds: $45K
3% more capital invested
Capital invested by funds: $110M → $113M (+$3M)
10% less funds holding
Funds holding: 61 → 55 (-6)
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
37% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 19
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.06M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$989K |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$965K |
| 4 |
Millennium Management
New York
|
+$691K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$304K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.6M |
| 2 |
BlackRock
New York
|
-$2.44M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.38M |
| 4 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$985K |
| 5 |
State Street
Boston,
Massachusetts
|
-$884K |
PHAS Hedge Fund Activity: Q2 2021 in Review
55 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q2 2021, worth a combined $113M — up 2.7% from $110M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PHAS and 13 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 12 added.
The largest buyer was Candriam SCA, opening a new position worth an estimated $2.06M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.6M sold.
- 55 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q2 2021, down from 61 in Q1 2021.
- Funds reported $113M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q2 2021, up 2.7% quarter-over-quarter.
- 13 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 19 closed out, a net change of -6 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was Candriam SCA, an estimated $2.06M added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was Sphera Funds Management, an estimated $2.6M sold.
Based on aggregated 13F filings for Q2 2021.